Aminoadamantanes: from treatment of Parkinson’s and Alzheimer’s disease to symptom amelioration of long COVID-19 syndrome?

References

• Harrison AG, Lin T, Wang P. Mechanisms of SARS-CoV-2 transmission and pathogenesis. Trends Immunol. 2020;41(12):1100–1115.
   PubMed Web of Science ®Google Scholar
• Agyeman AA, Chin KL, Landersdorfer CB, et al. Smell and taste dysfunction in patients with COVID-19: a systematic review and meta-analysis. Mayo Clin Proc. 2020;95(8):1621–1631.
   PubMed Web of Science ®Google Scholar
• Saniasiaya J, Narayanan P. Parosmia post COVID-19: an unpleasant manifestation of long COVID syndrome. Postgrad Med J. 2022;98(e2):e96.
   PubMed Web of Science ®Google Scholar
• Managing COVID-19. symptoms (including at the end of life) in the community: summary of NICE guidelines. BMJ. 2020;369:m1461.
   PubMedGoogle Scholar
• Lopez-Leon S, Wegman-Ostrosky T, Perelman C, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep. 2021;11(1):16144.
   PubMed Web of Science ®Google Scholar
• Premraj L, Kannapadi NV, Briggs J, et al. Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: a meta-analysis. J Neurol Sci. 2022;434:120162.
   PubMed Web of Science ®Google Scholar
• Shivani F, Kumari N, Bai P, et al. Long-term symptoms of COVID-19: one-year follow-up study. Cureus. 2022;14(6):e25937.
   PubMed Web of Science ®Google Scholar
• da Silva CGL, Santana JR, Pinheiro LF, et al. Anatomopathological aspects and clinical correlation of COVID-19: a systematic review. Adv Exp Med Biol. 2021;1353:217–224.
   PubMedGoogle Scholar
• Berlit P, Bösel J, Gahn G, et al. Neurological manifestations of COVID-19 - guideline of the German society of neurology. Neurol Res Pract. 2020;2(1):51
   PubMedGoogle Scholar
• Davies WL, Grunert RR, Haff RF, et al. Antiviral activity of 1-adamantamine (Amantadine). Science. 1964;144(3620):862–863.
   PubMedGoogle Scholar
• Fink K, Nitsche A, Neumann M, et al. Amantadine inhibits SARS-CoV-2 in vitro. Viruses. 2021;13(4):539. epub.
   PubMed Web of Science ®Google Scholar
• Schwab RS. Amantadine in the treatment of Parkinson’s disease. JAMA. 1969;208(7):1168–1170.
   PubMed Web of Science ®Google Scholar
• Müller T, Kuhn W, Möhr JD. Evaluating ADS5102 (amantadine) for the treatment of Parkinson’s disease patients with dyskinesia. Expert Opin Pharmacother. 2019;20(10):1181–1187.
   PubMed Web of Science ®Google Scholar
• Aoki FY, Sitar DS. Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacokinet. 1988;14(1):35–51.
   PubMed Web of Science ®Google Scholar
• Danysz W, Dekundy A, Scheschonka A, et al. Amantadine: reappraisal of the timeless diamond-target updates and novel therapeutic potentials. J Neural Transm (Vienna). 2021;128(2):127–169. .
   PubMed Web of Science ®Google Scholar
• Kornhuber J, Bormann J, Hübers M, et al. Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol. 1991;206(4):297–300.
   PubMed Web of Science ®Google Scholar
• Cortes-Borra A, randa-Abreu GE. Amantadine in the prevention of clinical symptoms caused by SARS-CoV-2. Pharmacol Rep. 2021;73(3):962–965.
   PubMed Web of Science ®Google Scholar
• Cortes BA. Does amantadine have a protective effect against COVID-19?. Neurol Neurochir Pol. 2020;54(3):284–285.
   PubMed Web of Science ®Google Scholar
• Smieszek SP, Przychodzen BP, Polymeropoulos MH. Amantadine disrupts lysosomal gene expression: a hypothesis for COVID19 treatment. Int J Antimicrob Agents. 2020;55(6):106004.
   PubMed Web of Science ®Google Scholar
• Jimenez-Jimenez FJ, Alonso-Navarro H, García-Martín E, et al. Anti-inflammatory effects of amantadine and memantine: possible therapeutics for the treatment of covid-19? J Pers Med. 2020;10(4):217. Epub.
   PubMed Web of Science ®Google Scholar
• Tipton PW, Wszolek ZK. What can Parkinson’s disease teach us about COVID-19? Neurol Neurochir Pol. 2020;54(2):204–206.
   PubMed Web of Science ®Google Scholar
• Müller T. GOCOVRI((R)) (amantadine) extended-release capsules in Parkinson’s disease. Neurodegener Dis Manag. 2022;12(1):15–28.
   PubMed Web of Science ®Google Scholar
• Comi G, Leocani L. Assessment, pathophysiology and treatment of fatigue in multiple sclerosis. Expert Rev Neurother. 2002;2(6):867–876.
   PubMedGoogle Scholar
• Iaccarino MA, Philpotts LL, Zafonte R, et al. Stimulant use in the management of mild traumatic brain injury: a qualitative literature review. J Atten Disord. 2020;24(2):309–317.
   PubMed Web of Science ®Google Scholar
• Nourbakhsh B, Revirajan N, Morris B, et al. Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial. Lancet Neurol. 2021;20(1):38–48.
   PubMed Web of Science ®Google Scholar
• Perez DQ, Espiritu AI, Jamora RDG. Efficacy and safety of amantadine for the treatment of fatigue in multiple sclerosis: a systematic review and meta-analysis. Neurodegener Dis Manag. 2020;10(6):383–395.
   PubMed Web of Science ®Google Scholar
• Generali JA, Cada DJ. Amantadine: multiple sclerosis-related fatigue. Hosp.Pharm. 2014;49(8):710–712.
   PubMedGoogle Scholar
• Nourbakhsh B. Serious side effects of amantadine: rethinking the benefits and risks of medications for MS fatigue. Mult Scler. 2021;27(14):2290.
   PubMed Web of Science ®Google Scholar
• Kraus MF, Smith GS, Butters M, et al. Effects of the dopaminergic agent and NMDA receptor antagonist amantadine on cognitive function, cerebral glucose metabolism and D2 receptor availability in chronic traumatic brain injury: a study using positron emission tomography (PET). Brain Inj. 2005;19(7):471–479.
   PubMed Web of Science ®Google Scholar
• Leclerc AM, Riker RR, Brown CS, et al. Amantadine and modafinil as neurostimulants following acute stroke: a retrospective study of intensive care unit patients. Neurocrit Care. 2021;34(1):102–111.
   PubMed Web of Science ®Google Scholar
• Kamel WA, Kamel MI, Alhasawi A, et al. Effect of pre-exposure use of amantadine on COVID-19 infection: a hospital-based cohort study in patients with Parkinson’s disease or multiple sclerosis. Front Neurol. 2021;12:704186.
   PubMed Web of Science ®Google Scholar
• Rejdak K, Grieb P. Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment. Mult Scler Relat Disord. 2020;42:102163.
   PubMed Web of Science ®Google Scholar
• Rejdak K, Fiedor P, Bonek R, et al. The use of amantadine in the prevention of progression and treatment of COVID-19 symptoms in patients infected with the SARS-CoV-2 virus (COV-PREVENT): study rationale and design. Contemp Clin Trials. 2022;116:106755.
   PubMed Web of Science ®Google Scholar
• Rejdak K, Grieb P. Fluvoxamine and amantadine: central nervous system acting drugs repositioned for COVID-19 as early intervention. Curr Neuropharmacol. 2022;20(4):777–781.
   PubMed Web of Science ®Google Scholar
• Folch J, Busquets O, Ettcheto M, et al. Memantine for the treatment of dementia: a review on its current and future applications. J Alzheimers Dis. 2018;62(3):1223–1240.
   PubMed Web of Science ®Google Scholar
• Danysz W, Parsons CG, Kornhuber J, et al. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents–preclinical studies. Neurosci Biobehav Rev. 1997;21(4):455–468.
   PubMed Web of Science ®Google Scholar
• Danysz W, Parsons CG, Quack G. NMDA channel blockers: memantine and amino-aklylcyclohexanes–in vivo characterization. Amino Acids. 2000;19(1):167–172.
   PubMed Web of Science ®Google Scholar
• Parsons CG, Danysz W, Quack G. Memantine and the amino-alkyl-cyclohexane MRZ 2/579 are moderate affinity uncompetitive NMDA receptor antagonists–in vitro characterisation. Amino Acids. 2000;19(1):157–166.
   PubMed Web of Science ®Google Scholar
• Honegger UE, Quack G, Wiesmann UN. Evidence for lysosomotropism of memantine in cultured human cells: cellular kinetics and effects of memantine on phospholipid content and composition, membrane fluidity and beta-adrenergic transmission. Pharmacol Toxicol. 1993;73(4):202–208.
   PubMedGoogle Scholar
• Riederer P, Ter MV. Coronaviruses: a challenge of today and a call for extended human postmortem brain analyses. J Neural Transm (Vienna). 2020;127(9):1217–1228.
   PubMed Web of Science ®Google Scholar
• Caumont AS, Octave JN, Hermans E. Amantadine and memantine induce the expression of the glial cell line-derived neurotrophic factor in C6 glioma cells. Neurosci Lett. 2006;394(3):196–201.
   PubMed Web of Science ®Google Scholar
• Li WJ, Chen H-J, Qian L-H, et al. [Effects of glial cell line-derived neurotrophic factor and memantine on long-term prognosis in neonatal rats with periventricular leukomalacia]. Zhongguo Dang Dai Er Ke Za Zhi. 2011;13(9):743–746.
   PubMedGoogle Scholar
• Rajasekar N, Nath C, Hanif K, et al. Inhibitory Effect of Memantine on Streptozotocin-Induced Insulin Receptor Dysfunction, Neuroinflammation, Amyloidogenesis, and Neurotrophic Factor Decline in Astrocytes. Mol Neurobiol. 2016;53(10):6730–6744.
   PubMed Web of Science ®Google Scholar
• Ranju V, Sathiya S, Kalaivani P, et al. Memantine exerts functional recovery by improving BDNF and GDNF expression in 3-nitropropionic acid intoxicated mice. Neurosci.Lett. 2015;586:1–7.
   PubMed Web of Science ®Google Scholar
• Grossberg GT, Alva G, Hendrix S, et al. Memantine ER maintains patient response in moderate to severe alzheimer’s disease: post hoc analyses from a randomized, controlled, clinical trial of patients treated with cholinesterase inhibitor. Alzheimer Dis Assoc Disord. 2018;32(3):173–178.
   PubMed Web of Science ®Google Scholar
• Müller T. What are the main considerations when prescribing pharmacotherapy for Parkinson’s disease? Expert.Opin.Pharmacother. 2022;23(7):745–750.
   PubMed Web of Science ®Google Scholar
• Gao Y, Ma L, Liang F, et al. The use of amantadine in patients with unresponsive wakefulness syndrome after severe cerebral hemorrhage. Brain Inj. 2020;34(8):1084–1088.
   PubMed Web of Science ®Google Scholar
• Ishida T, Obara Y, Kamei C. Studies on wakefulness-promoting effect of memantine in rats. BehavBrain Res. 2010;206(2):274–278.
   Google Scholar
• Reynolds JC, Rittenberger JC, Callaway CW. Methylphenidate and amantadine to stimulate reawakening in comatose patients resuscitated from cardiac arrest. Resuscitation. 2013;84(6):818–824.
   PubMed Web of Science ®Google Scholar
• Terzano MG, Montanari E, Calzetti S, et al. The effect of amantadine on arousal and EEG patterns in Creutzfeldt-Jakob disease. Arch.Neurol. 1983;40(9):555–559.
   PubMedGoogle Scholar
• Falsafi Z, Tafakhori A, Agah E, et al. Safety and efficacy of memantine for multiple sclerosis-related fatigue: a pilot randomized, double-blind placebo-controlled trial. J Neurol Sci. 2020;414:116844.
   PubMed Web of Science ®Google Scholar
• Garssen MP, Schmitz PI, Merkies IS, et al. Amantadine for treatment of fatigue in Guillain-Barre syndrome: a randomised, double blind, placebo controlled, crossover trial. J Neurol Neurosurg Psychiatry. 2006;77(1):61–65.
   PubMed Web of Science ®Google Scholar
• Lovera JF, Frohman E, Brown TR, et al. Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial. Mult Scler. 2010;16(6):715–723.
   PubMed Web of Science ®Google Scholar
• Miller P, Soundy A. The pharmacological and non-pharmacological interventions for the management of fatigue related multiple sclerosis. J Neurol Sci. 2017;381:41–54.
   PubMed Web of Science ®Google Scholar
• Sailer M, Heinze H-J, Schoenfeld M, et al. Amantadine influences cognitive processing in patients with multiple sclerosis. Pharmacopsychiatry. 2000;33(1):28–37.
   PubMed Web of Science ®Google Scholar
• Ginde AA, Paredes R, Murray TA, et al. Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial. Lancet Respir Med. 2022; Epub.
   Web of Science ®Google Scholar
• Conte WL, Golzarri-Arroyo L. Tixagevimab and Cilgavimab (Evusheld) boosts antibody levels to SARS-CoV-2 in patients with multiple sclerosis on b-cell depleters. Mult Scler Relat Disord. 2022;63:103905.
   PubMed Web of Science ®Google Scholar
• Keam SJ. Tixagevimab + Cilgavimab: first Approval. Drugs. 2022;82(9):1001–1010.
   PubMed Web of Science ®Google Scholar
• Levin MJ, Ustianowski A, De Wit S, et al. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19. N Engl J Med. 2022;386(23):2188–2200.
   PubMed Web of Science ®Google Scholar
• Pringle A, Parsons E, Cowen LG, et al. Using an experimental medicine model to understand the antidepressant potential of the N -Methyl-D-aspartic acid (NMDA) receptor antagonist memantine. J Psychopharmacol. 2012;26(11):1417–1423.
   PubMed Web of Science ®Google Scholar
• Lv X, Li Q, Mao S, et al. The protective effects of memantine against inflammation and impairment of endothelial tube formation induced by oxygen-glucose deprivation/reperfusion. Aging (Albany NY). 2020;12(21):21469–21480.
   PubMedGoogle Scholar
• McAllister J, Ghosh S, Berry D, et al. Effects of memantine on mitochondrial function. Biochem Pharmacol. 2008;75(4):956–964.
   PubMed Web of Science ®Google Scholar
• Quarato G, Scrima R, Ripoli M, et al. Protective role of amantadine in mitochondrial dysfunction and oxidative stress mediated by hepatitis C virus protein expression. Biochem Pharmacol. 2014;89(4):545–556.
   PubMed Web of Science ®Google Scholar
• Shevtsova EF, Vinogradova D, Neganova ME, et al. Pharmacological sequestration of mitochondrial calcium uptake protects against dementia and beta-amyloid neurotoxicity. Sci Rep. 2022;12(1):12766.
   PubMed Web of Science ®Google Scholar
• Wang Y, Jiang B, Luo W. Memantine ameliorates oxaliplatin-induced neurotoxicity via mitochondrial protection. Bioengineered. 2022;13(3):6688–6697.
   PubMed Web of Science ®Google Scholar
• Müller T, Mueller BK, Riederer P. Perspective: treatment for Disease Modification in Chronic Neurodegeneration. Cells. 2021;10(4):873.
   PubMed Web of Science ®Google Scholar
• Takahashi-Ito K, Makino M, Okado K, et al. Memantine inhibits beta-amyloid aggregation and disassembles preformed beta-amyloid aggregates. Biochem Biophys Res Commun. 2017;493(1):158–163.
   PubMed Web of Science ®Google Scholar
• Zhang W, Kandel N, Zhou Y, et al. Drug delivery of memantine with carbon dots for Alzheimer’s disease: blood-brain barrier penetration and inhibition of tau aggregation. J Colloid Interface Sci. 2022;617:20–31.
   PubMed Web of Science ®Google Scholar
• Bodnar W, Aranda-Abreu G, Słaboń-Willand M, et al. The efficacy of amantadine hydrochloride in the treatment of COVID-19 - a single-center observation study. Pol Merkur Lekarski. 2021;49(294):389–393.
   PubMedGoogle Scholar
• Butterworth RF. Potential for the repurposing of adamantane antivirals for COVID-19. Drugs R D. 2021;21(3):267–272.
   PubMed Web of Science ®Google Scholar
• Toft-Bertelsen TL, Jeppesen MG, Tzortzini E, et al. Amantadine has potential for the treatment of COVID-19 because it inhibits known and novel ion channels encoded by SARS-CoV-2. Commun Biol. 2021;4(1):1347.
   PubMed Web of Science ®Google Scholar
• Tronche C, Lestage P, Louis C, et al. Pharmacological modulation of contextual “episodic-like” memory in aged mice. Behav Brain Res. 2010;215(2):255–260.
   PubMed Web of Science ®Google Scholar
• Tur C. Fatigue management in multiple sclerosis. Curr Treat Options Neurol. 2016;18(6):26.
   PubMed Web of Science ®Google Scholar
• Wiwanitkit V. Amantadine, COVID-19 and Parkinsonism. Arch Med Res. 2020;51(7):714.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Gammeltoft KA, Galli A, et al. Efficacy of ion-channel inhibitors amantadine, memantine and rimantadine for the treatment of SARS-CoV-2 in vitro. Viruses. 2021;13(10):2082.
   PubMed Web of Science ®Google Scholar
• Zoladz PR, Campbell A, PARK C, et al. Enhancement of long-term spatial memory in adult rats by the noncompetitive NMDA receptor antagonists, memantine and neramexane. Pharmacol Biochem Behav. 2006;85(2):298–06.
   PubMed Web of Science ®Google Scholar
• Klosch G, Zeitlhofer J, Ipsiroglu O. Revisiting the concept of vigilance. Front Psychiatry. 2022;13:874757.
   PubMed Web of Science ®Google Scholar
• Molina JL, Voytek B, Thomas ML, et al. Memantine effects on electroencephalographic measures of putative excitatory/inhibitory balance in schizophrenia. Biol Psychiatry Cogn Neurosci Neuroimaging. 2020;5(6):562–568.
   PubMedGoogle Scholar
• Schulz H, Jobert M, Coppola R, et al. The use of diurnal vigilance changes in the EEG to verify vigilance-enhancing effects of memantine in a clinical pharmacological study. Neuropsychobiology. 1996;33(1):32–40.
   PubMed Web of Science ®Google Scholar
• Thrash-Williams B, Ahuja M, Karuppagounder SS, et al. Assessment of therapeutic potential of amantadine in methamphetamine induced neurotoxicity. Neurochem Res. 2013;38(10):2084–2094.
   PubMed Web of Science ®Google Scholar
• Schwab RS, England AC Jr. Amantadine HCL (Symmetrel) and its relation to Levo-Dopa in the treatment of Parkinson’s disease. Trans Am Neurol Assoc. 1969;94:85–90.
   PubMedGoogle Scholar
• Rascol O, Tönges L, deVries T, et al. Immediate-release/extended-release amantadine (OS320) to treat Parkinson’s disease with levodopa-induced dyskinesia: analysis of the randomized, controlled ALLAY-LID studies. Parkinsonism Relat Disord. 2022;96:65–73.
   PubMed Web of Science ®Google Scholar